Aerovate Therapeutics (AVTE) Expected to Announce Earnings on Monday

Key Points

• Aerovate Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of $0.25 per share.
• The company's stock currently trades at $6.89, with a significant drop from its 52-week high of $105.00.
• Institutional investors have shown increased interest, with several firms boosting their stakes in Aerovate Therapeutics during the first quarter.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data on Monday, August 11th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Aerovate Therapeutics Stock Down 6.5%

NASDAQ:AVTE traded down $0.51 during mid-day trading on Friday, hitting $7.32. 116,595 shares of the stock traded hands, compared to its average volume of 12,438. The stock has a market capitalization of $212.17 million, a price-to-earnings ratio of -2.45 and a beta of 0.95. Aerovate Therapeutics has a 52 week low of $56.35 and a 52 week high of $105.00. The firm's 50 day moving average is $8.64 and its two-hundred day moving average is $47.75.

Hedge Funds Weigh In On Aerovate Therapeutics

Several hedge funds have recently added to or reduced their stakes in AVTE. AQR Capital Management LLC boosted its position in Aerovate Therapeutics by 14.7% in the 1st quarter. AQR Capital Management LLC now owns 21,633 shares of the company's stock valued at $54,000 after buying an additional 2,779 shares during the period. Rhumbline Advisers boosted its position in Aerovate Therapeutics by 67.3% in the 1st quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock valued at $57,000 after buying an additional 9,154 shares during the period. Jane Street Group LLC purchased a new stake in Aerovate Therapeutics in the 1st quarter valued at about $28,000. Finally, Goldman Sachs Group Inc. boosted its position in Aerovate Therapeutics by 12.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 352,669 shares of the company's stock valued at $885,000 after buying an additional 38,300 shares during the period.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.